Cannabidiol for Individuals at Risk for Alzheimer's Disease: A Randomized Placebo Controlled Trial
This is a double-blind, randomized controlled trial designed to test the effects of cannabidiol (CBD) on validated biomarkers of Alzheimer's disease (AD) progression, and behavioral, neurocognitive, and clinical measures, with putative mechanisms of action.
• Must be between the ages of 55 - 85 and provide valid informed consent.
• Participant must receive a diagnosis of Mild Cognitive Impairment after a careful cognitive and functional evaluation by a clinician.
• Functional Activities Questionnaire (FAQ) score of 8 or less and self-reported ability to function independently
• Montreal Cognitive Assessment (MoCa) score is between 18-25
• Participant must have a CDR score of .5 on the Clinical Dementia Rating scale (CDR), which includes an assessment of function and is often used to distinguish MCI from dementia.
• Must have an informant that will be utilized over the course of the 24 week study (must be the same person throughout study)
• Participant must pass a test of consent comprehension
• Must be interested in using CBD to help with cognitive function
• Must plan on living in the Denver metro area over the next 6 months
⁃ Able to attend in-person visits at the study site